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Introduction {#sec001}
============

Norovirus is a single-stranded RNA (+) virus belonging to the family *Caliciviridae*. It is transmitted orally by infected people or contaminated food. It causes severe vomiting, diarrhea, and fever 24--48 h after infection \[[@pone.0237888.ref001]\]. The main foods associated with norovirus gastroenteritis are oysters and other bivalves, although recently, numerous outbreaks of norovirus caused by unheated food products, such as salads and ready-to-eat food, have been reported \[[@pone.0237888.ref002], [@pone.0237888.ref003]\]. Every year, norovirus is responsible for 64,000 episodes of diarrhea requiring hospitalization, and up to 200,000 deaths of children \< 5 years of age in developing countries \[[@pone.0237888.ref004]\].

Although many norovirus-inactivating methods have been reported, including thermal treatment, ultraviolet irradiation, high hydrostatic pressure, hypochlorous acid, and the use of food-derived components \[[@pone.0237888.ref001], [@pone.0237888.ref005]--[@pone.0237888.ref007]\]; these methods are suboptimal as they affect the taste and color of food products. Consequently, the development of an anti-norovirus disinfectant agent is an important issue for food hygiene.

Lysozyme is a single-chain polypeptide consisting of 129 amino acids \[[@pone.0237888.ref008]\]. It catalyzes the hydrolysis of peptidoglycan of gram-positive bacteria. It is contained in secretions, such as tears and saliva, and egg white \[[@pone.0237888.ref008]\]. In addition, lysozyme is extracted on an industrial scale from chicken egg white and is widely used as a food additive or as a raw material for pharmaceuticals.

We have reported that thermally denatured lysozyme (DL) inactivates norovirus \[[@pone.0237888.ref009]\]. The particle size of murine norovirus strain 1 (MNV-1), a surrogate for norovirus, shows an average expansion of 16.37 nm after exposure to DL for 1 h, and the N-terminal region of lysozyme possibly contributes to the inactivating effect \[[@pone.0237888.ref009]\]. Furthermore, DL inactivates norovirus in several foods and is also effective against the hepatitis A virus \[[@pone.0237888.ref010]--[@pone.0237888.ref012]\]. However, the conditions for optimal DL norovirus-inactivating effects and the underlying mechanism remain unclear.

This study aimed to analyze the norovirus-inactivating conditions and mechanisms of DL. We evaluated the conditions under which DL is highly effective against norovirus, together with the changes in the gene expression of norovirus-infected host cells infected with DL-treated MNV-1. We also analyzed the involvement of specific lysozyme domains in the antiviral effect. The data suggest that residues 5--39 of lysozyme contribute to the antiviral effect of DL. These observations will inform the use of DL as an anti-norovirus disinfectant of foods.

Materials and methods {#sec002}
=====================

Virus and cells {#sec003}
---------------

MNV-1, kindly provided by Dr. Herbert W. Virgin from Washington University, was propagated in RAW264.7 macrophages (ATCC^®^ TIB-71^TM^) cultured at 37°C under 5% CO~2~ in Dulbecco's modified Eagles medium (DMEM, FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) containing 5% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 μg/mL). After confirmation of the cytopathic effect during incubation at 37°C under 5% CO~2~, the cells were subjected to four cycles of freezing and thawing, and were then centrifuged at 8000 × *g* for 20 min. The supernatant was used as an MNV-1 stock solution and stored at --80°C until use.

Plaque assay for MNV-1 infectivity determination {#sec004}
------------------------------------------------

The infectivity of MNV-1 was determined by a plaque assay, as described previously \[[@pone.0237888.ref009]\]. Briefly, RAW264.7 cells were seeded into 6-well plates (Falcon BD, Franklin Lakes, NJ) at approximately 6 log cells/mL in DMEM containing 5% (v/v) FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL). The plates were incubated at 37°C under 5% CO~2~ for 18 h. Then, 500 μL/well of samples prepared as described below sections were added to the plates, and the plates were shaken at 20 r/min for 1 h. The inoculated sample was removed, and the wells overlaid with 2 mL of 1.5% (v/v) SeaPlaque agarose (Lonza Japan, Tokyo, Japan) in DMEM containing 5% (v/v) FBS. The plates were incubated at 37°C under 5% CO~2~ for 48 h. Then, 2 mL of 0.03% (v/v) neutral red solution (Sigma-Aldrich Japan, Tokyo, Japan) was added, and the plates incubated at 37°C under 5% CO~2~ for 1 h. Thus, visualized plaques were then counted.

Varying pH values of DL preparations and MNV-1 inactivation {#sec005}
-----------------------------------------------------------

DL was prepared as previously described \[[@pone.0237888.ref011]\]. Briefly, egg white lysozyme (FUJIFILM Wako Pure Chemical) was suspended in distilled water at a concentration (w/v) of 0.2%, 1.0%, and 2.0%; the initial pH (3.7) was adjusted to 4.5, 5.5, 6.5, 7.5, and 8.5 by the addition of 1 N NaOH. After passing through a 0.2-μm filter, the filtrate was heated in an oil bath at 100°C for 40 min and then cooled on ice.

For the virus inactivation experiment, 500 μL of MNV-1 suspension \[approximately 6 log plaque-forming units (PFU)/mL\] was mixed with 500 μL of DL preparation, for the final DL concentration of 0.1%, 0.5%, and 1.0%. The mixtures were allowed to stand for 1 min (for 1.0% DL final concentration) or 1 h (for 0.1% and 0.5% DL final concentrations). The samples were then diluted 10-fold in DMEM to stop the virus inactivation reaction and analyzed by the plaque assay, as described above.

Characterization of DL prepared at different pH values {#sec006}
------------------------------------------------------

Hydrophobicity, thiol group content, and circular dichroism (CD) spectra of the different DL preparations were analyzed. Hydrophobicity was measured by using protein stability and aggregation assay kit (PSA200K, Profoldin, Hudson, MA), according to the manufacturer's instructions. Sample excitation was measured at 550 nm and emission at 610 nm, using a spectrofluorometer (SH-9000, Corona Electric Co., Ltd., Ibaraki, Japan). Thiol group content was determined in a reaction mixture containing 192 μL of deionized water, 20 mM Tris-HCl at pH 8.0, 2.8 μL of Ellman's reagent \[prepared by dissolving 4 mg of 5,5′-dithiobis-(2-nitrobenzoic acid) powder in 1 mL of Tris buffer at pH 7.0\], and 200 μL of 1.0% (w/v) DL. After incubation at room temperature for 1 h in the dark, sample absorbance was measured at 412 nm by using a microplate reader (SH-1000 Lab, Corona Electric Co., Ltd.). CD spectra were acquired using a circular dichroism dispersometer (J-720, JASCO Corporation, Tokyo, Japan). For the analysis, DL preparation was diluted to 100 μg/mL in distilled water, and the spectra acquired in the range of 190 to 250 nm, with a scanning speed of 100 nm/min, a bandwidth of 1 nm, and integration frequency of 10.

Gene expression analysis of RAW264.7 macrophages infected with DL-treated MNV-1 {#sec007}
-------------------------------------------------------------------------------

RAW264.7 cell monolayers (1 × 10^7^ cells/mL) in T25 cell flasks (Thermo Fisher Scientific K. K., Tokyo, Japan) were inoculated as described below.

Live MNV-1 (6 log PFU/mL) was used at a multiplicity of infection (MOI) of 0.01. For some experiments, MNV-1 (6 log PFU/mL) was inactivated by heating at 100°C for 40 min in an oil bath. The heat-treated MNV-1 was then used at MOI of 0.01 (infectivity as determined before heat inactivation). For another set of experiments, 100 μL of MNV-1 (6 log PFU/mL) was mixed with 100 μL of 2.0% of DL (adjusted at pH 6.5 before thermally-denaturation) and allowed to stand at room temperature for 60 min. The mixture was used at MOI of 0.01 (infectivity as before DL treatment).

The inoculated RAW264.7 cell monolayers were incubated at 37°C under 5% CO~2~ for 24 h. The cells were then detached by using a cell scraper (Thermo Fisher Scientific) and centrifuged at 300 × *g* for 5 min. Mock infections were performed using the cell culture medium \[DMEM containing 5% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL)\].

Total RNA was extracted from inoculated RAW264.7 macrophages using the RNeasy Mini kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. The extracted RNA was reverse-transcribed using the PrimeScript RT reagent kit (Takara Bio, Shiga, Japan). Briefly, 8 μL of sample RNA was mixed with 2 μL of 5× PrimeScript buffer, 0.5 μL of PrimeScript RT Enzyme mix I, 25 pmol of oligo dT primer, and 50 pmol of random hexamer primers. The reverse-transcription was performed using a thermal cycle GeneAmp PCR system 9700 (GE Healthcare Japan, Tokyo, Japan), at 37°C for 15 min, followed by a denaturation step at 85°C for 5 s. The resulting cDNA was amplified by quantitative polymerase chain reaction (qPCR) to quantitate the expression levels of interferon β (*Ifnb*) and interleukin 6 (*Il6*) genes \[[@pone.0237888.ref013]\]. For the qPCR reaction, 2 μL of cDNA was mixed with 12.5 μL of 2 × TB Green Premix Ex Taq II (Takara Bio), 8.5 μL of distilled water, and 0.4 μM of primers specific for the *Ifnb* or *Il6* genes, as previously described \[[@pone.0237888.ref013]\]. Amplification was performed using a QuantStudio 3 Realtime PCR system (Life Technologies Japan Ltd., Tokyo, Japan) with 95°C of denaturation for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. Fold-changes in mRNA abundance were calculated by the ΔΔCt method, as previously described \[[@pone.0237888.ref014]\].

Verification of the inactivation domain in lysozyme {#sec008}
---------------------------------------------------

It was previously reported that lysozyme (PDB ID: 6BO2) residues 5--39 inactivate MNV-1 \[[@pone.0237888.ref009]\]. In the current study, three peptide variants (R1, R2, and R3) of the target sequence (Lzm 5--39), a peptide containing lysozyme residues 1--35 (Lzm 1--35), and one containing residues 88--125 (Lzm 88--125) were designed ([Table 1](#pone.0237888.t001){ref-type="table"}). All the designed peptides were synthesized by Eurofin K. K. (Tokyo, Japan).

10.1371/journal.pone.0237888.t001

###### Peptides used in the current study[^a^](#t001fn001){ref-type="table-fn"}.

![](pone.0237888.t001){#pone.0237888.t001g}

  Peptide            Amino acid sequence                                                    No. residues (AA)   M~w~
  ------------------ ---------------------------------------------------------------------- ------------------- ---------
  **Lzm 5--39**      RCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFN                                    35                  3993.47
  **Lzm 5--39 R1**   RCELAAAMKR[**E**]{.ul}GLDNYRGYSLGNWVCAA[**E**]{.ul}FESNFN              35                  3986.36
  **Lzm 5--39 R2**   RCELAAAMKRHGLDNYRGYSLGN[**N**]{.ul}VCAAK[**N**]{.ul}ESN[**N**]{.ul}N   35                  3855.22
  **Lzm 5--39 R3**   RC[**N**]{.ul}LAAAMKRHGL[**N**]{.ul}NYRGYSLGNWVCAAKF[**N**]{.ul}SNFN   35                  3962.46
  **Lzm 1--35**      KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFE                                    35                  3962.54
  **Lzm 88--125**    ITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIR                                 38                  4220.82

^a^ Mutated amino acids relative to the original sequence (Lzm 5--39) are shown in bold and underlined. Theoretical molecular weight is provided.

The synthesized peptides were dissolved in distilled water to the same molarity as 2.0% (w/v) lysozyme, 14,307 of molecular weight, and heated in an oil bath at 100°C for 40 min, then immediately cooled in ice. Next, 120 μL of MNV-1 solution at 6 log pfu/mL was mixed with 120 μL of the prepared heat-denatured peptides, and allowed to stand for 60 min at room temperature. The samples were immediately diluted 10-fold in DMEM and analyzed by the plaque assay, as described above.

Statistical analysis {#sec009}
--------------------

Experiments were independently performed in triplicate. Values for the CD spectra are expressed as the mean, and other values are expressed as the mean ± standard deviation (SD). Significant differences were analyzed by Dunnett's test by using Microsoft Excel ver. 1908 (Microsoft Japan, Tokyo, Japan). The significance threshold was set at *p* \< 0.05.

Results {#sec010}
=======

Relationship between pH value of DL preparations and MNV-1 inactivation {#sec011}
-----------------------------------------------------------------------

Exposure of MNV-1 to 1.0% DL prepared at different pH values resulted in a decrease of MNV-1 infectivity. The inactivation efficiency of DL increased with the preparation pH, with the most pronounced effects observed at pH ≥ 6.5. ([Fig 1A](#pone.0237888.g001){ref-type="fig"}). The infectivity of MNV-1 after exposure to DL preparations at pH 4.5--8.5 was significantly lower than that of the control (*p* \< 0.01). Furthermore, upon exposure to DL preparations at pH 6.5--8.5, the infectivity of MNV-1 was below the detection limit (1.0 log PFU/mL). Similarly, when MNV-1 was exposed to 0.1% and 0.5% of DL preparations at different pH for 60 min, the infectivity of MNV-1 tended to decrease as the pH of DL preparations increased ([Fig 1B](#pone.0237888.g001){ref-type="fig"}).

![Infectivity of MNV-1 after exposure to DL preparations at different pH values.\
(A) MNV-1 was exposed to distilled water (Control) or 1% DL for 1 min. (B) MNV-1 was exposed to distilled water (Control), or 0.1%, or 0.5% of DL for 60 min. Values are expressed as the mean ± SD (*n* = 3). The dashed line indicates the detection limit of the plaque assay. Significant differences between the control and sample (exposed to DL) values were analyzed by Dunnett's test and shown; \*\**p* \< 0.01.](pone.0237888.g001){#pone.0237888.g001}

Characteristics of DL prepared at different pH values {#sec012}
-----------------------------------------------------

The surface hydrophobicity of native lysozyme and DL prepared at different pH values was determined. The fluorescence of DL samples was significantly higher than that of native lysozyme at any pH (*p* \< 0.01) ([Fig 2A](#pone.0237888.g002){ref-type="fig"}). In addition, the fluorescence intensity of DL preparations tended to increase as the pH increased, with DL preparations at pH 7.5 showing the maximum value. Furthermore, assessment of the free thiol group content, based on sample absorbance, revealed that the absorbance of DL preparations was significantly higher than that of native lysozyme at any pH value (*p* \< 0.01) ([Fig 2B](#pone.0237888.g002){ref-type="fig"}). Sample absorbance tended to increase with an increasing pH of the DL preparation.

![Protein characteristics of DL at different pH values.\
For the experiments, the pH of the native lysozyme (Native Lzm) solution was adjusted to pH 4.5--8.5 by using 1 N NaOH. DL (1%) was prepared by denaturation at 100°C for 40 min. (A) Surface hydrophobicity of 1% lysozyme solution prepared at different pH values. Samples were mixed with 1X PSA solution, and sample fluorescence intensity was determined (λ~Ex~ = 550 nm, λ~Em~ = 610 nm). Values are expressed as the mean ± SD (*n* = 3). (B) Thiol group content in 1% lysozyme solution at different pH values. Samples were mixed with Ellman's reagent, and sample absorbance was determined at 412 nm. Values are expressed as the mean ± SD (*n* = 3). (C) CD spectra of lysozyme preparations. The spectra are shown as an average of triplicate measurements. (A, B) Significant differences between native Lzm and DL preparations at the same pH value are shown; \*\**p* \< 0.01.](pone.0237888.g002){#pone.0237888.g002}

The CD spectra of native lysozyme and DL preparations were analyzed. Negative maxima at 208 nm and 222 nm, derived from the α-helix, were observed in the native lysozyme and DL preparations at pH 3.7--5.5 but not in DL preparations at pH 6.5--8.5 ([Fig 2C](#pone.0237888.g002){ref-type="fig"}). This indicated reduced α-helix content in DL preparations at pH 6.5--8.5.

Gene expression analysis of RAW264.7 macrophages infected with DL-treated MNV-1 {#sec013}
-------------------------------------------------------------------------------

RAW264.7 macrophages were infected with MNV-1 under various conditions, and the expression of selected cytokine genes was analyzed by qPCR. When MNV-1 was used at MOI = 0.01, the expression of the *Ifnb* and *Il6* genes significantly increased as compared to mock-infected cells (*p* \< 0.01, [Fig 3](#pone.0237888.g003){ref-type="fig"}). However, when MNV-1 had been inactivated by heat treatment or exposed to DL prior to the infection, the expression of the two genes did not increase ([Fig 3](#pone.0237888.g003){ref-type="fig"}).

![Expression of the interferon-β and interleukin-6 genes in RAW264.7 macrophages infected with MNV-1.\
The macrophages were infected with MNV-1 at MOI = 0.01. The following MNV-1 preparations were used: live MNV-1; MNV-1 heat-inactivated at 100°C for 10 min (Heat-treated MNV-1); and MNV-1 that had been exposed to 1.0% DL and adjusted to a pH of 6.5 before thermal denaturation for 60 min (DL-treated MNV-1). Mock treatment involved incubation with DMEM containing 5% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL). Gene expression was determined by qPCR. Fold-changes (relative to mock treatment samples) were calculated using the ΔΔCt method. Values are expressed as the mean ± SD (*n* = 3). Significant differences between the mock and other samples are shown; \*\**p* \< 0.01.](pone.0237888.g003){#pone.0237888.g003}

Verification of the lysozyme inactivation domain {#sec014}
------------------------------------------------

Three variants of Lzm 5--39 were designed, and their inactivating effects against MNV-1 were evaluated. In the R1 variant, few basic amino acids were replaced with acidic amino acids to set the acidic/basic amino acid ratio to 1. As a result of amino acid substitution, the charge of the R1 variant decreased from +3 (Lzm 5--39) to -1. In addition, its hydropathy index \[[@pone.0237888.ref015]\] was -18.1, which was similar to that of Lzm 5--39 (-18.2).

In the R2 variant, hydrophobic amino acids were replaced to reduce the hydrophobicity without changing the charge. As Lzm 5--39 has many hydrophobic amino acids, the replacement of all these amino acids might prevent peptide synthesis. Thus, only aromatic amino acids were replaced. The charge of the resulting R2 peptide was +3, the same as Lzm 5--39, and the hydropathy index changed to -33.2.

In the R3 variant, all acidic amino acids were replaced with uncharged amino acids. The replacement resulted in a net charge of +6. Furthermore, two additional peptides (Lzm 1--35, and Lzm 88--125) from a different region of the lysozyme were synthesized, and the respective MNV-1 inactivating effects were also evaluated. The hydropathy plot was computed using the ProtScale tool with Kyte & Doolittle scale \[[@pone.0237888.ref015]\] in ExPASy \[[@pone.0237888.ref016]\] ([S1 Fig](#pone.0237888.s001){ref-type="supplementary-material"}).

[Fig 4](#pone.0237888.g004){ref-type="fig"} shows a decrease in MNV-1 infectivity after exposure to DL (Lzm 1--129), Lzm 5--39, and replacement variants (R1--R3) after thermal denaturation. The infectivity of MNV-1 decreased by 0.9 log PFU/mL for Lzm 1--129 (pH 3.7, a final concentration of 1.0%) and by 1.7 log PFU/mL for the heat-denatured Lzm 5--39. In the case of the R1 and R2 variants, the inactivating effect of heat-denatured peptides against MNV-1 was lost; however, for the R3 variant, the MNV-1 infectivity was reduced by 2.0 log PFU/mL. The inactivating effect of the R3 variant was higher than that of Lzm 5--39 and the entire protein (Lzm 1--129). The MNV-1 infectivity was reduced by 1.7 and 0.2 log PFU/mL, by Lzm 1--35 and Lzm 88--125, respectively. Furthermore, both Lzm 1--35 and Lzm 5--39 treatments similarly reduced MNV-1 infectivity ([Fig 4](#pone.0237888.g004){ref-type="fig"}).

![MNV-1 inactivation by heat-denatured Lzm peptides.\
Different lysozyme peptides were analyzed. All peptides and the entire lysozyme (amino acids 1--129) at the same molar concentration as that of 1.0% (w/v) lysozyme were heat-denatured at 100°C for 40 min. MNV-1 (approximately 6 log PFU/mL) was mixed with DL (1%, w/v, pH 3.7) or the peptides for 60 min. The values are expressed as the mean of log reduction of MNV-1 ± SD (*n* = 3). Significant differences between the reduction in the infectivity of the whole protein (1--129) and that of each sample are shown; \*\**p* \< 0.01.](pone.0237888.g004){#pone.0237888.g004}

Moreover, CD spectrum analysis of Lzm 5--39 revealed that the negative maxima at 208 nm and 222 nm, derived from the α-helix and observed in the unheated sample, were reduced in the heat-denatured sample ([S2 Fig](#pone.0237888.s002){ref-type="supplementary-material"}).

Discussion {#sec015}
==========

In the present study, we aimed to analyze norovirus-inactivating conditions and the mechanism of DL. We showed that (1) the inactivating effect of DL was increased by adjusting the pH to 6.5 or higher before thermal denaturation; (2) MNV-1 treated with DL did not affect the innate gene expression of host cells; and (3) the hydrophobicity of the protein structure. Of note, residues 5--39 primarily contributed to the antiviral effect of DL. These observations imply that the hydrophobic amino acids (particularly residues 5--39) of lysozyme, after exposure to thermal denaturation, interact with the structural protein of MNV-1, which contains multiple hydrophobic amino acids, thereby leading to the inactivation of MNV-1.

Although it was previously shown that the inactivating effect of DL is enhanced by increasing the heating temperature and heating time \[[@pone.0237888.ref009]\], other conditions may also contribute to the inactivating effect of DL. Therefore, to comprehensively evaluate the conditions under which DL is highly active against norovirus, the effect of the pH of the DL preparation was examined. As the pH of the lysozyme solution increased, the inactivating effect of DL also increased ([Fig 1](#pone.0237888.g001){ref-type="fig"}). The hydrophobicity and thiol group content significantly increased with the pH of the DL solution ([Fig 2A and 2B](#pone.0237888.g002){ref-type="fig"}).

Lysozyme is a positively charged protein with an isoelectric point of 11. We anticipated that in a high-pH solution (pH 6.5--8.5), the intermolecular forces would become stronger, thus, denaturing the protein structure upon heating. In other words, adjusting the pH to a high value would trigger the loosening of the protein structure during thermal denaturation. As shown in [Fig 2A and 2B](#pone.0237888.g002){ref-type="fig"}, the higher the pH, the higher the hydrophobicity and thiol group content of DL. This suggests that thermal denaturation disrupts the protein structure, exposing the otherwise buried hydrophobic amino acids. Of note, lysozyme also has many disulfide bonds, with multiple hydrophobic amino acids in the vicinity of cysteine residues \[[@pone.0237888.ref008]\].

We, therefore, speculate that the disulfide bonds were broken by thermal denaturation, exposing the nearby hydrophobic amino acids. As determined by the CD spectra of DL, heat denaturation reduced the α-helical content of the protein ([Fig 2C](#pone.0237888.g002){ref-type="fig"}), also indicating considerable changes in the secondary DL structure during thermal denaturation at pH 6.5 or higher.

We further evaluated the innate expression of host cells infected by DL-treated MNV-1. According to Enosi Tuipulotu *et al*. \[[@pone.0237888.ref013]\], MNV infection of RAW264.7 macrophages perturbs the transcriptional profile of host genes involved in interferon signaling, viral recognition, and cytokine stimulation, including the *Ifnb* and *Il6* genes. When RAW264.7 macrophages were infected with heat-inactivated MNV-1, MNV-1 was not recognized and did not affect the transcription of *Ifnb* and *Il6* genes ([Fig 3](#pone.0237888.g003){ref-type="fig"}). Similarly, DL-treated MNV-1 did not induce cytokine expression in macrophages. This indicated that the interaction between DL and MNV-1 was irreversible, and the treated virus was unable to enter and replicate in the host cell. This suggests that MNV-1 was completely inactivated by DL and did not regain infectivity.

Finally, to identify the virus-inactivating domain of lysozyme, we designed Lzm 5--39 replacement peptides, namely variants R1--R3 ([Table 1](#pone.0237888.t001){ref-type="table"}). Data shown in [Fig 4](#pone.0237888.g004){ref-type="fig"} suggest that the hydrophobicity and positive charge of Lzm 5--39 contribute to the inactivating effect of DL. An increase in the positive peptide charge could have enhanced the inactivating effect of the R3 variant, as it facilitated the absorption of the negatively charged virus particles by DL \[[@pone.0237888.ref017]\].

We also examined the effects of the Lzm 1--35 peptide in comparison with the Lzm 5--39 peptide. Lysozyme residues 1--4 form a random coil region containing three hydrophobic amino acids (VFG) ([Table 1](#pone.0237888.t001){ref-type="table"}). Therefore, we expected that the virus-inactivating activity of Lzm 1--35 would be higher than that of Lzm 5--39. However, the activity was equivalent to that of Lzm 5--39 ([Fig 4](#pone.0237888.g004){ref-type="fig"}), which implied that the hydrophobicity of the heated protein structure was more important than the hydrophobicity of the primary structure. Based on the results shown in [Fig 4](#pone.0237888.g004){ref-type="fig"}, results in [Fig 2A and 2B](#pone.0237888.g002){ref-type="fig"} imply that the heat denaturation-related increase in surface-exposed hydrophobicity of DL contributes to the virus-inactivating effect, not merely hydrophobicity of DL.

We also examined the Lzm 88--125 peptide (encompassing three C-terminal helical structures of lysozyme). However, the peptide reduced MNV-1 infectivity by only 0.2 log PFU/mL, which was significantly lower than the effect observed for other peptides ([Fig 4](#pone.0237888.g004){ref-type="fig"}). This suggests that the structure of the N-terminal region of lysozyme contributes to viral inactivation, and that the hydrophobicity and positive charges of Lzm 5--39 region contribute to the inactivating effect of DL. This is supported by the observation that the α-helical content of heat-denatured Lzm 5--39 was lower than that of unheated Lzm 5--39 ([S2 Fig](#pone.0237888.s002){ref-type="supplementary-material"}).

Lysozyme lyses gram-positive bacteria by hydrolyzing the cell wall peptidoglycan, acting as a muramidase \[[@pone.0237888.ref018]\]. Ibrahim *et al*. \[[@pone.0237888.ref019]\] reported that heat-treated (80°C for 30 min) lysozyme inactivates gram-negative bacteria. According to Sugahara *et al*. \[[@pone.0237888.ref020]\], the inactivating effect of DL against gram-negative bacteria is not associated with enzymatic activity but rather, with the hydrophobic amino acid residues of lysozyme exposed during heat denaturation and their association with the outer membrane of gram-negative bacteria. These considerations are in line with the data presented herein. An exposed loop region in the P domain corresponding to the surface of an MNV-1 structural protein contains multiple hydrophobic amino acids \[[@pone.0237888.ref021]\]. Therefore, we propose that the interaction of these hydrophobic amino acids with the hydrophobic amino acids of lysozyme exposed by thermal denaturation leads to MNV-1 inactivation.

Ibrahim *et al*. \[[@pone.0237888.ref022]\] reported that residues 46--61, 62--68, and 98--112 of lysozyme are deamidated by thermal denaturation and easily bind to monovalent and divalent cations. Therefore, these regions are considered to be the inactivating domain of DL effective against gram-negative bacteria. However, as shown in the current study, lysozyme residues 5--39 inactivated MNV-1, whereas residues 88--125 exerted no such inactivating effect ([Fig 4](#pone.0237888.g004){ref-type="fig"}). We, therefore, propose that although the mechanism of norovirus inactivation by lysozyme is similar to that of gram-negative bacteria inactivation, the lysozyme inactivation domain differs in the two cases.

Based on the presented data, (1) the MNV-1--inactivating effect of DL is enhanced by adjusting the pH of the lysozyme solution to 6.5 or higher before thermal denaturation; (2) the reaction of DL and MNV-1 is irreversible, and MNV-1 is completely inactivated by DL; and (3) the hydrophobicity and positive charge of lysozyme contribute to virus inactivation by DL. Hydrophobicity and positive charge are contradictory protein properties, and further detailed studies are required to resolve this observation. Hydrophobicity was implied to be more important in the protein structure than the hydrophobicity as the primary structure. Nonetheless, the findings of the current study may inform the practical use of DL as a disinfectant against norovirus. For instance, adjusting the pH conditions before thermal denaturation might aid the development of a cost-effective disinfectant, and a lysozyme fragment synthesized industrially might be useful as a novel disinfectant. We foretell that in the near future, DL might be used as a disinfectant in a wide range of food processes.

Supporting information {#sec016}
======================

###### Hydropathicity of synthesized peptides used in the current study.

Hydropathicity was computed by ExPASy \[[@pone.0237888.ref016]\] ProtScale using the Kyte & Doolittle scale \[[@pone.0237888.ref015]\]. (A) Lzm 5--39, (B) Lzm 5--39 variants (R1, R2, and R3), (C) Lzm 1--35, and (D) Lzm 88--125.

(TIF)

###### 

Click here for additional data file.

###### CD Spectra of a peptide containing lysozyme residues 5 to 39 (Lzm 5--39).

Peptide concentration was adjusted to 900 μM and heat-denatured at 100°C for 40 min (Heated 5--39) or not (Unheated 5--39). The spectra are an average of triplicate measurements.

(TIF)

###### 

Click here for additional data file.
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Please submit your revised manuscript by Aug 30 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Oscar Millet

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2.  Thank you for stating the following in the Financial Disclosure section:

\"This work was supported by Grant-in-Aid for JSPS Fellows Grant Number 17J05482,

and Grant-in-Aid for Scientific Research (B) Grant Number 17H03872.\"

We note that one or more of the authors are employed by a commercial company: \"Kewpie Corporation,\"

a\) Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

b)  Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. 

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [[http://journals.plos.org/plosone/s/competing-interests](about:blank)]{.ul}) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [[http://journals.plos.org/plosone/s/competing-interests](about:blank)]{.ul}

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In previous work (10.1038/srep11819), the authors demonstrated that thermal/structural denaturation activates residues Lz23-57 (Lzm 5-39?) of egg white lysozyme in order to inactivate norovirus, a food contaminant. The present work explores the optimal inactivating conditions of denatured lysozyme. Optimal and complete inactivation of the glycoside hydrolase was found by raising the pH of the egg-white lysozyme solution above 6.5 prior to irreversible thermal denaturation, which reduced alpha helical content in CD spectra. Hydrophobic residues spanning the region 5-39 in the lysozyme sequence were posited to contribute to inactivation based on data for three mutant constructs. These findings are of relevance to the use of disinfectants in industrial food production.

1\) It is not clear why the residues are numbered differently in the two reports by the authors (Lz 23-57 vs. Lzm 5-39).

2\) The rationale for why/how the authors chose the three peptide variants is not entirely clear. The overall basic/positive peptide (6 basic, 3 acidic groups, pI = 11) was made to be either R1: neutral and amphiphilic (H-\>E and K-\>E mutations); R2: hydrophilic instead of hydrophobic (Asn instead of one Trp and two Phe); or R3: polar and more positive (3 acidic sidechains replaced with Asn). For instance, unlike Phe, tryptophan is a polar residue. Inactivation was lost with R1 and R2 and reduced in R3. It seems an oversimplification to say that the results show that 5-39 "hydrophobicity" is responsible for inactivation. Please describe the mutations/variants in the Abstract.

3\) Line 310: it is presumably the "surface-exposed" hydrophobic and thiol content that increases with denaturation. The logic of mere "increased hydrophobicity" particularly breaks down in Lines 336-342. Lzm 1-35 and Lzm 5-39 were equivalent, so it seems that structural/surface changes upon denaturation are the culprit rather than the mere presence of hydrophobic residues (such as VFG). The authors propose that the exposed hydrophobic sequences bind the norovirus capsid rather than lysozyme having enzymatic activity, similar to the mechanism of gram-negative activation.

4\) The readability of the manuscript could be improved by reorganizing passages. Methodological details are included in the Figure captions. The paragraph in the Discussion describes the effect of the mutant variants on protein charge, but this rationale is not explained in the earlier Introduction/Methods/Results sections. The Discussion would benefit from breaking up into subheadings/sections.

Reviewer \#2: In this manuscript, Takahashi et al attempt to delineate the mechanism of inactivation of murine norovirus by heat-denatured hen egg white lysozyme (DL). They show that increasing the pH to 6.5-8.5 before thermal denaturation increase the effectiveness of DL. It is known from an earlier study that residues 5-39 was the most effective at virus inhibition. Here the authors introduce mutations to modify net charge and hydrophobicity and conclude that both hydrophobicity as well positive charge of this peptide contribute to viral inhibition. It is also interesting that a simple clustering of hydrophobic residues in the primary sequence is not sufficient, rather the results with peptide 88-125 in this paper along with alpha-lactalbumin from a previous study (Takahashi et al, Scientific Reports, 2015) suggest that exposure of hydrophobic and charged residues in a particular conformation must be responsible for this. Of course, it is hard to imagine a 'conformation' in a heat denatured protein, and hence further studies are needed.

Overall, the results presented in the paper are interesting, clear and understandable, and backed with evidence. As such it merits publication in Plos One, however a few issues need to be addressed before acceptance.

1\. It would be good to include a hydropathy plot for each peptide along with the mutant variants.

2\. Does the 5-39 peptide become totally unstructured in the presence of some denaturant? It is easy to get that information from a CD spectrum in the presence of some urea. This experiment will confirm that even the heat denatured peptide has some residual structure. Also, can you obtain CD spectrum of the heat denatured peptide in multiple batches and overlay? This will also make sure that this residual conformation is consistent every time you denature different batches.

3\. You mention that increase in thiol content upon denaturation might be due to SS bonds breaking during heating. While this is possible, it would be great to quantify how many actually break (using Ellman's reagent). This should be straight forward to do.

4\. The organization of the manuscript needs to be changed. For example, there are several details about peptide design, and interpretation which are in the Methods and Discussion, while ideally, they should all be part of the Results. It is very difficult to go back and forth while reading. Methods should not contain the logic behind doing an experiment, rather should only focus on the technical details. Results of hydropathy index calculation are all included in Discussion, which again should move to Results.

5\. The word 'Denatured' in keywords is misspelt.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: **Yes: **Ron Hills

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237888.r002
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Reponses to reviewer \#1

1\) It is not clear why the residues are numbered differently in the two reports by the authors (Lz 23-57 vs. Lzm 5-39).

Thank you for your comments and suggestions. We found them quite useful as we approached our revision.

\- Sorry for confusing. In the previous report (Takahashi et al., 2015. Sci. Rep. 5: 11819), the reference sequence of lysozyme (GenBank ID: AAL69327) is a chicken lysozyme chromatin domain containing a lysozyme sequence at residues 19-145 (Chong et al., 2002. Nucleic Acids Res. 30:463-467). In this sequence, residues of 23-57 correspond to Lzm 5-39 of the lysozyme sequence (PDB ID: 6BO2).

2\) The rationale for why/how the authors chose the three peptide variants is not entirely clear. The overall basic/positive peptide (6 basic, 3 acidic groups, pI = 11) was made to be either R1: neutral and amphiphilic (H-\>E and K-\>E mutations); R2: hydrophilic instead of hydrophobic (Asn instead of one Trp and two Phe); or R3: polar and more positive (3 acidic sidechains replaced with Asn). For instance, unlike Phe, tryptophan is a polar residue. Inactivation was lost with R1 and R2 and reduced in R3. It seems an oversimplification to say that the results show that 5-39 "hydrophobicity" is responsible for inactivation. Please describe the mutations/variants in the Abstract.

\- As you pointed out, the description about the background of peptide-design was not sufficient in the manuscript.

\- In the R1 variant, in order to make the number of acidic and basic amino acids the same, 2 out of 6 basic amino acids were replaced with acidic amino acids. Here, the hydropathy index was calculated to confirm that the hydropathy was almost the same as before replacement.

\- The R2 variant was aimed to change only the hydrophobicity without changing the charge. Lzm 5-39 originally had a large number of hydrophobic amino acids, and the replacement of all of the residues might prevent peptide-synthesis. Therefore, we decided to replace only the aromatic amino acids, which has a particularly high degree of hydrophobicity.

\- In the R3 variant, all the acidic amino acids were replaced with uncharged amino acids in order to shift the basic side.

\- The background of peptide design was added into the revised manuscript (P. 15, L. 253-268 in Revised Manuscript with Track Change). We also revised abstract section to describe the peptide mutation/variants (P. 2, L. 31-37 in Revised Manuscript with Track Change).

\- As you commented, it cannot be concluded that only hydrophobicity contributes to virus-inactivating effect from the Fig. 4. Further study is needed to elucidate which of the characters, positive charge and hydrophobicity, dominates the virus-inactivation mechanism. It has been described in the manuscript (P. 22, L. 379-382 in Revised Manuscript with Track Change).

3\) Line 310: it is presumably the "surface-exposed" hydrophobic and thiol content that increases with denaturation. The logic of mere "increased hydrophobicity" particularly breaks down in Lines 336-342. Lzm 1-35 and Lzm 5-39 were equivalent, so it seems that structural/surface changes upon denaturation are the culprit rather than the mere presence of hydrophobic residues (such as VFG). The authors propose that the exposed hydrophobic sequences bind the norovirus capsid rather than lysozyme having enzymatic activity, similar to the mechanism of gram-negative activation.

\- Fig. 4 implies that the surface-exposed hydrophobicity is important for virus inactivation, rather than the mere hydrophobicity of heat-denatured lysozyme as your comment. On the other hand, since it could not be asserted that "surface-exposed hydrophobicity is important" with Fig. 2 only. In response to the suggestion, we added sentence "" after the consideration of Fig. 4 (P. 20 L. 345-347 in Revised Manuscript with Track Change).

4\) The readability of the manuscript could be improved by reorganizing passages. Methodological details are included in the Figure captions. The paragraph in the Discussion describes the effect of the mutant variants on protein charge, but this rationale is not explained in the earlier Introduction/Methods/Results sections. The Discussion would benefit from breaking up into subheadings/sections.

\- The structure of paragraph was reorganized as suggested by both reviewer \#1 and reviewer \#2. The description of mutant peptides, hydropathy index calculation, and hydropathy plot have been moved to the results section based on the proposal of reviewer \#2 (P. 15 L. 253-268 in Revised Manuscript with Track Change).

 

Responses to reviewer \#2

1\. It would be good to include a hydropathy plot for each peptide along with the mutant variants.

We appreciate your comments and suggestions, which have helped us significantly improve the paper. We tried to be responsive to your concerns.

\- Hydropathy plot for each peptide was added in this revision as suggested (S Fig. 1).

2\. Does the 5-39 peptide become totally unstructured in the presence of some denaturant? It is easy to get that information from a CD spectrum in the presence of some urea. This experiment will confirm that even the heat denatured peptide has some residual structure. Also, can you obtain CD spectrum of the heat denatured peptide in multiple batches and overlay? This will also make sure that this residual conformation is consistent every time you denature different batches.

3\. You mention that increase in thiol content upon denaturation might be due to SS bonds breaking during heating. While this is possible, it would be great to quantify how many actually break (using Ellman's reagent). This should be straight forward to do.

\- As your suggestion, acquiring CD spectrum in the presence of some urea and quantifying SS bonds could further enhance the manuscript. However, unfortunately we are unable to perform these additional experiments due to the current COVID-19 pandemic.

4\. The organization of the manuscript needs to be changed. For example, there are several details about peptide design, and interpretation which are in the Methods and Discussion, while ideally, they should all be part of the Results. It is very difficult to go back and forth while reading. Methods should not contain the logic behind doing an experiment, rather should only focus on the technical details. Results of hydropathy index calculation are all included in Discussion, which again should move to Results.

\- We reorganized manuscript as your suggestion. In particular, some descriptions about peptide design, hydropathy index calculation, and hydropathy plot were moved to in the results section (P. 15, L. 253-268 in the Revised Manuscript with Track Change).

5\. The word 'Denatured' in keywords is misspelt.

\- "Denatured" in keywords was corrected in this revision.

Again, thank you for taking the time and energy to help us improve the paper. We are hopeful that our revision helps to improve your opinion of work.

###### 

Submitted filename: Responses to reviewers.docx

###### 

Click here for additional data file.
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Impact of pH and protein hydrophobicity on norovirus inactivation by heat-denatured lysozyme

PONE-D-20-14783R1

Dear Dr. Takahashi,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Oscar Millet

Academic Editor

PLOS ONE

Additional Editor Comments (optional):
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PONE-D-20-14783R1

Impact of pH and protein hydrophobicity on norovirus inactivation by heat-denatured lysozyme

Dear Dr. Takahashi:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Oscar Millet

Academic Editor

PLOS ONE
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